NSAIDs: Risk of acute MI compared with remote use

Slides:



Advertisements
Similar presentations
Obat anti inflamasi non steroid
Advertisements

Department of Health and Human Services Center for Drug Evaluation and Research Review of Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs.
NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.
NSAIDS in the ischaemic heart disease patient
Presentations in this series 1.Introduction 2.Self-matching 3.Proxies 4.Intermediates 5.Instruments 6.Equipoise Avoiding Bias Due to Unmeasured Covariates.
Non-steroidal Anti-inflammatory Drugs (NSAIDs) By: NOR AZIRAH BINTI ILIAS eHSO7- HS225.
Canadian Cardiovascular Society Antiplatelet Guidelines
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 44 Antiinflammatory and Antigout Drugs.
Infliximab TNF- α antagonist Watch for infections.
Pharmacology-1 PHL nd Term 6 th Lecture By Abdelkader Ashour, Ph.D. Phone:
Nonsteroidal Antiinflammatory Drugs (NSAIDs)
RISKS of NSAIDS: Focus on GI Risks of Over-the-Counter NSAIDs Byron Cryer, M.D. University of Texas Southwestern Medical School.
A Risk-Benefit Analysis of the use of NSAIDs in the Management of Arthritis Anne-Barbara Mongey, MD, DCH, MRCPI Associate Professor of Internal Medicine.
Non Steroidal Anti Inflammatory Drugs, Nonopioid Analgesics By S.Bohlooli, PhD.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 44 Antiinflammatory, Antirheumatic, and Related.
Propionic acid derivatives Ibuprofen, naproxen, fenoprofen, flurbiprofen, oxaprozin,→ anti-inflammatory, analgesic, and antipyretic.  These drugs are.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
An epidemiologic perspective on etoricoxib David J. Graham, MD, MPH Office of Surveillance and Epidemiology April 12, 2007.
Donor deferral due to intake of anti-platelet medication Sharyn Orton, Ph.D. Jaro Vostal, M.D., Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
BluntPenetrating Placebo rFVIIa Patients (%) n=20 n=8 n=9 n=4 P=0.03 P=0.068 Adapted from Rizoli S. Canadian Anesthesiologists’
Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Chapter 44 Antiinflammatory and Antigout Drugs 1 Fall 2012.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.
- nonsteroidal anti-inflammatory drugs (NSAIDs), are used to combat inflammation. - Their antiinflammatory action equals that of aspirin. - have analgesic.
ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:
NSAIDs: Risk of acute MI compared with remote use Largest NSAID database study ever casts doubt on entire coxib controvers [Rheumawire > News; Jun 10,
AINEs Jorge H. Ramírez Farmacología Universidad del Valle.
Risk of GI Bleed on NSAIDs Professor Michael Langman International Ibuprofen Foundation University of Birmingham, UK.
Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial Glenn M. Eisen, M.D., M.P.H. Associate.
Hot Topic Presentation Lars Halford, GP ST3 March 2010
Pharmaceutical Chemistry II Lecture 5 - NSAIDS
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk of Bleeding With Dabigatran in Atrial Fibrillation.
Pharmaceutical Chemistry II LectureS 6 & 7 - NSAIDS
NSAIDS NOTES and Tables
Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Rachel Kim, PharmD Candidate Cone Health Family Medicine
NSAID: Non-Steroid Anti-Inflammatory Drugs
Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
“Traditional NSAIDs” versus “COXIBs”
NSAIDS NOTES and Tables
Volume 120, Issue 3, Pages (February 2001)
Nonsteroidal Anti-Inflammatory Drugs(NSAIDs)
Update on NSAID Use:.
Drug used within 3 months of index date Adjusted odds ratio* p
Analgesics.
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
PREMIER: Rate of hypertension at 18 months
PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.
Analgesics Review 8 December :38 AM.
Relative risk of major events with atenolol vs placebo
Adjusted odds ratio for hypoglycemia with gatifloxacin and levofloxacin compared with macrolide antibiotics Antibiotic Odds ratio of hypoglycemia 95% CI.
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial  Daniel H. Solomon, MD, MPH, M. Elaine.
Trial Selection Process
Number of patients who received at least one prescription for a COX-2 inhibitor or NSAID after hospital discharge Drug Patients % of study cohort Rofecoxib.
Update on OTC Pain Relievers for Osteoarthritis
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Cystatin C levels and risk of death from all causes
NSAIDs Epidemiology NSAIDs amounts to 3.8 of all prescriptions
Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.
Treating Osteoarthritis
Patient characteristics: American vs Canadian transplant patients
Rahilly-Tierney CR et al. Circulation 2009;120:1491-7
Results of Searches and Screening of Potentially Relevant Studies
Davide Capodanno et al. JCIN 2009;2:
Benefit from Earlier Intervention
Employment of patients with AS compared with controls, by BASDAI
Presentation transcript:

NSAIDs: Risk of acute MI compared with remote use Unadjusted odds ratio Adjusted odds ratio 95% CI p Indomethacin 1.65 1.71 1.35-2.17 <0.0001 Sulindac 1.46 1.41 1.01-1.96 0.04 Meloxicam 1.34 1.37 1.05-1.78 0.02 Rofecoxib 1.32 1.22-1.42 Piroxicam 1.14 1.18 0.90-1.54 0.22 Other NSAIDs 1.22 0.94-1.46 0.15 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.

NSAIDs: Risk of acute MI compared with remote use Unadjusted odds ratio Adjusted odds ratio 95% CI p Ibuprofen 1.08 1.11 1.01-1.22 0.02 Celecoxib 1.09 1.02-1.15 0.008 Naproxen 1.03 0.95-1.22 0.22 Diclofenac 1.04 1.05 0.93-1.19 0.43 Valdecoxib 0.99 0.72-1.37 0.97 Ketoprofen 0.88 0.86 0.63-1.18 0.35 Nabumetone 0.83 0.60-1.14 0.26 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.

NSAID use in cohort study Drug use Patients Patient-years Percentage of cohort Celecoxib 299 550 220 201 46.04 Diclofenac 109 402 44 488 16.82 Ibuprofen 371 051 109 666 57.03 Indomethacin 40 168 9266 6.17 Ketoprofen 18 575 7577 2.86 Meloxicam 26 123 8413 4.02 Nabumetone 25 286 8368 3.89 Naproxen 172 295 51 645 26.48 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.

NSAID use in cohort study Drug use Patients Patient-years Percentage of cohort Other NSAIDs 90 539 32 832 13.92 Piroxicam 22 212 9243 3.41 Rofecoxib 209 974 112 760 32.27 Sulindac 15 906 6087 2.44 Valdecoxib 26 526 6161 4.08 Total 650 590 2 356 884.5   Aspirin 203 233 241 816 31.24 Singh G, et al. EULAR 2005; June 8-11, 2005; Vienna, Austria.